KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Beginning Cash Balance: 2017-2024

Historic Beginning Cash Balance for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $23.9 million.

  • Aquestive Therapeutics' Beginning Cash Balance fell 32.64% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 212.61%. This contributed to the annual value of $23.9 million for FY2024, which is 12.47% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Beginning Cash Balance stood at $23.9 million for FY2024, which was down 12.47% from $27.3 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Beginning Cash Balance high stood at $49.3 million for FY2020, and its period low was $23.9 million during FY2024.
  • Its 3-year average for Beginning Cash Balance is $26.4 million, with a median of $27.3 million in 2023.
  • Data for Aquestive Therapeutics' Beginning Cash Balance shows a maximum YoY tumbled of 35.52% (in 2021) over the last 5 years.
  • Aquestive Therapeutics' Beginning Cash Balance (Yearly) stood at $49.3 million in 2020, then crashed by 35.52% to $31.8 million in 2021, then dropped by 11.89% to $28.0 million in 2022, then fell by 2.68% to $27.3 million in 2023, then decreased by 12.47% to $23.9 million in 2024.